抗新型冠状病毒中和抗体药物的研究进展  

Progress of Neutralizing Antibodies Against SARS-CoV-2

作　　者：那一凡 金鹏飞[1] 倪倩[1] 谭琳[1] 陈露露[1] 谭玲[1] NA Yifan;JIN Pengfei;NI Qian;TAN Lin;CHEN Lulu;TAN Ling(Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)

机构地区：[1]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730

出　　处：《中国医院用药评价与分析》2022年第11期1400-1403,1408,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家重点研发计划项目(No.2020YFC2008300)。

摘　　要：新型冠状病毒肺炎疫情在全球范围的持续发展促使人们开展针对该疾病的深入研究,包括治疗药物的研究。中和抗体药物作为一种很有前景的特异性抗病毒药已成功应用于部分病毒感染性疾病的治疗。目前,国际上针对新型冠状病毒(SARS-CoV-2)中和抗体的研发进展十分迅速,已有多个抗体药物获得紧急使用授权。本文主要通过SARS-CoV-2中和抗体的作用靶点、药物研究进展以及需要关注的问题与不足等方面进行综述。The ongoing global development of the COVID-19 epidemic has led to in-depth research on the disease,including therapeutic agents.As a promising specific antiviral agents,the neutralizing antibodies have been successfully applied on some viral infectious diseases.Currently,the development of neutralizing antibodies against SARS-CoV-2 is progressing rapidly internationally,several antibodies have been authorized for emergency use.This paper reviews the effect targets of neutralizing antibodies against SARS-CoV-2,the research progress of drugs,and the problems and shortcomings that need attention.

关 键 词：新型冠状病毒 中和抗体 研究进展 临床试验 

分 类 号：R978[医药卫生—药品]